Janssen drug-resistant TB med granted 6-month US review
This article was originally published in Scrip
Executive Summary
The US FDA granted a six-month priority review to Janssen Research & Development for its new drug application (NDA) for bedaquiline (TMC207) as part of combination therapy for pulmonary, multi-drug resistant tuberculosis (MDR-TB) in adults.